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Highlights 
•The Melanoma App market is a high turnover one – almost half of Apps in 
2014 no longer existed in 2017 
•The evidence base of many of these Apps is improving however remains 
limited with the vast majority of Apps not peer reviewed or associated with 
clinician or scientific involvement in their development or review  
•The costs of the Apps, especially those providing clinician consultations are 
significant and may be prohibitive for many users 
•The most common function of melanoma Apps in 2017 is in aiding users to 
monitor and track their own moles over time.  
 
ABSTRACT  
Background: Smartphone applications (“apps”) exist for primary and secondary prevention of melanoma. Our 
aim was to review currently available apps for community, patient and generalist clinician users.   
Design: Prospective study, April 2017 – May 2017 
Main outcomes: Appropriate apps available to Android and Apple smartphones were assessed in regards to app 
specific information (target user, cost, store rating, last update), functions offered and clinician, professional or 
scientific input and or peer review. Comparison was made with a similar 2014 review of the app market. 
Results: 43 apps meeting inclusion criteria were found. Compared to 2014, 24 of 43 (55.8%) were new, and apps 
performing automated image analysis declined from 46.1% to 23.3% market share. 23 of 43 (53.4%) were free 
to download, 48.8% (n=20) required payments of some form. The most common functionality was 
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monitoring/tracking with 24 of 43 (55.8%) apps performing this. 15 of 43 apps (34.9%) reported clinician, 
professional or scientific input; in 2014 it was only 4 of 39 (10.3%). 2 of 43 apps (5%) mentioned peer-reviewed 
evidence along with professional input . Not all apps had ratings. On Android 20 of 22 apps had ratings; average 
app rating was 3.5, range 1.6 to 4.6. On Apple, 13 of 13 had ratings; average rating was 3.5; range 1 to 5.  
Conclusions: Since 2014 there have been an expanding and changing landscape of apps targeting melanoma 
diagnosis.. There remains a lack of evidence backing their efficacy. This is concerning given their public 
availability and the gravity of their subject matter.  
 
Introduction 
Smartphones Apps for healthcare are increasingly available. There are estimates that over 80,000 
different smartphone Apps for healthcare exist for the Android operating system alone1. There is 
therefore great interest in Apps that could aid skin cancer primary or secondary prevention or assist 
consumers to track their moles for changes over time (one of the key warning signs for melanoma)2.  
The global incidence of skin cancers, in particular melanoma, has steadily increased over the last 50 
years in most fair skinned populations3. Indeed, while rates of melanoma have stabilized in Australia 
and New Zealand, rates continue to rise in the USA and most European countries3. This rise has been 
suggested to result from changed attitudes towards sun exposure and increasing surveillance and 
community awareness of skin cancer3. Nevertheless, while these Apps may theoretically empower 
consumers, the evidence backing their efficacy or safety remains limited. Many experts have urged 
consumers to exercise caution when deciding to use smartphone Apps for health-related purposes 4-
6.  
Kassianos et al. published a landmark review of such Apps in 20146. They found that there were 39 
Apps available on either Apple or Android App stores, which they grouped into four types of 
functionality 1) Information provision, 2) Monitoring and tracking of lesions, 3) Algorithmic image 
analysis, or 4) Teledermatological services 6.  
One of the criticisms raised by the review was the lack of integration of these Apps with current 
clinical or scientific evidence, with only one App demonstrating a single reference to a peer-
reviewed publication6. Other research studies assessing the benefit of Melanoma Apps which use 
algorithms to analyse smartphone images of pigmented lesions. This independent peer review 
assessment concluded that such apps do not confer any additional benefit to patients compared 
with normal skin self-assessment without Melanoma Apps 7 8, 9. The degree of benefit smartphone 
App education provides for melanoma primary prevention has also been called into question. A 2015 
randomized clinical trial into the impact of sun-safety information provided by Apps showed only a 
weak improvement in sun protection10. Regulation is also complex and inconsistent. For example, 
the United State’s Food and Drug Administration (FDA) do not explicitly regulate Apps and instead 
use a discretionary and risk stratification approach11. Given the limited evidence supporting Apps, 
their widespread public availability and the varied nature of regulatory oversight, regular 
surveillance of how this App market has evolved is important.   
 
This review therefore aimed to assess and report on the changing landscape of skin cancer-related 
Apps directed at the general community, melanoma patients or clinician users since Kassianos et al’s 
2014 review. This review also aims to improve the evaluation by not only assessing the Apps based on 
their marketing description but also:  i) download each App and test their functionality 12; ii) 
summarise user ratings as a proxy for consumers’ satisfaction13; and iii) derive an up-to-date register 
of currently available smartphone Apps directed at groups listed above.  
 
Methods 
Search Protocol and Approach to App Identification  
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This protocol was designed following the Quality and Risk of Bias Checklist for Studies That Review 
Smartphone Applications9 (Appendix 1).  
We designed our App search and approach to reviewing each App on the Quality and Risk of Bias 
Checklist for Studies That Review Smartphone Applications12.  
Apps were included only if their description mentioned primary or secondary prevention of melanoma 
or tracking of spots, moles or skin cancers. We included Apps which required associated dermoscopes 
(magnifying lens attachments). In May 2017, the online App stores of Apple and Android were 
searched from Australia using the search terms “skin cancer”, “mole” and “melanoma” – the three 
terms previously used by Kassianos et al.6 For any Apps present in Kassianos et al. that did not Appear 
on this initial search, the name of each individual App was searched in order to confirm it was no 
longer available and had not been missed.  
Apps were excluded if they were targeted at specialist clinicians such as dermatologists or plastic 
surgeons, not in English, cosmetically focused, entertainment tools or were only booking tools for skin 
cancer clinics.  
A full list of all search terms and the search process is presented in Appendix 2. 
Assessment and Evaluation of Melanoma Apps 
Each App was downloaded onto an appropriate device and assessed by the principal investigator 
(A.G.N.), who analysed the functionalities, store description and App website if available. The 
operating systems (Android, Apple, both), stated target user (general population, melanoma patients, 
clinician), costs in US Dollars, online store ratings, number of raters, number of downloads (Android 
only) and date of last update were collated. On both the Apple and Google Play store, users can rate 
each App from a minimum of 0 to a maximum of 5 stars. For the Apple Store, we used the aggregate 
rating of all versions as opposed to “current rating” as it allowed for better comparison with the 
Google Play rating system which is also in aggregate.  
Next, the Apps were evaluated in terms of their functionalities and degree of professional, scientific 
or clinician input with their development or evaluation. Functionally, they were assessed in regard to 
whether they provided (i) information to consumers regarding melanoma or skin cancer primary 
prevention (UVR, Sun exposure prevention) or secondary prevention (skin self-examination); (ii) 
individual patient risk factor assessment; (iii) analysis of spots or moles either via proprietary algorithm 
or forwarding of images to a dermatologist or clinician; or (iv) tracking or monitoring lesions over time 
with or without the aid of a body map.  
Apps with professional, scientific or clinician input were thus divided into two groups; (1) those with 
peer reviewed evidence for their efficacy representing the gold standard and (2) those which had any 
other evidence of other scientific or professional body involvement in their development. This 
included any direct clinician involvement in development or endorsements by professional, scientific 
or academic bodies. This definition was used as while peer reviewed evidence for the app working as 
intended is certainly the gold standard, having professional, scientific or clinician input into app 
development may provide an indication for early steps towards validation. 
Results 
The findings are summarized in Table 1. Detailed summaries of the register are provided in Tables 2, 
3 and 4. 
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Overall, 43 smartphone Apps for melanoma were identified using the search criteria (Table 1). This is 
an increase in 10% from the 39 Apps reviewed in 20146. The largest proportion of Apps were for Apple 
devices only (n=21, 48.8%). 10 (23.3%) were for Android only and 12 (27.9%) Apps were available on 
both stores. 
 
Properties of Available Apps and Changes in the Market Since July 2014 
The majority of current Apps (n=24, 55.8%) were not featured in Kassianos et al., thus were assumed 
to be new developments since 2014. Only 17/39 (43.6%) Apps found in 2014 were still available 
reflecting a 56.4% (n=22) attrition rate (Table 1). Of the 22 Apps present in 2014 yet no longer 
available, 17/22 (77.3%) were Apple only or both platforms, while 5/22 (22.7%) were Android only 
(Table 2).  
 
In 2017, the most common functionality was monitoring/tracking of skin lesions (n=24, 55.8%) 
followed by information about melanoma or skin cancer prevention (n=22, 39.5%). In 2014, this was 
reversed, with the most common function being education about melanoma or skin cancer prevention 
(n=22, 56.4%) followed by monitoring and tracking (n=19, 48.7%) (Table 3). 
 
20 (46.5%) apps catalogue/classified lesions; 10 (23.3%) via algorithmic image analysis and 10 (23%) 
via dermatologist review. Algorithmic image analysis appeared to have decreased its market share 
since 2014 in absolute numbers and proportions with 18 of 39 (46.2%) apps in 2014 providing this 
compared to only 10 (23.3%) in 2017 (Table 3).   
 
Teledermatology as a proportion of the market was unchanged, with 10 of 43 apps (23.3%) in 2017 
and 9 of 39 (23.1%) in 2014 offering such services. 7/10 (70%) teledermatology apps found in this 
review were new developments since 2014.  In 2014, no app required dermoscopic attachments, but 
in 2017, 4 (9.3%) had associated dermoscopy (Table 3).  
 
Costs to Users 
23 (53.5%) of apps were completely free in 2017 while 20 (46.5%) required payments of some form 
(Table 1). Four different payment models were observed – ‘one off’ App purchases, ‘subscription’ 
based services, ‘pay per consultation’ services and payment for associated ‘dermoscopy attachments.’  
 
For one off purchases (n=9), costs ranged between $0.99 to $6.99 (mean $3.43). For subscriptions 
(n=3), 12-month costs ranged between $13.82 to $37.20 (mean $26.81). For pay per consultation Apps 
(n=7), 2 Apps had no set price with cost decided by the treating clinician, while 5 charged per 
consultation with costs ranging between $15 to $300.96 (mean $92.99). 1 app required a purchased 
dermoscope for full functionality. Inclusive of the above, dermoscopic attachments were offered by 3 
Apps and 4 different dermoscopic attachments were available. Costs ranged between $22.56 to 
$404.91 (mean $113.33) (Table 3).  
 
Professional, Clinician or Scientific Input  
Overall, 2 (n=2, 4.6%) apps provided peer-reviewed evidence for their efficacy, and 15 (n=15, 35%) 
apps reported input from clinicians or professional bodies. Only 2 of these 15 (13.3%) apps reported 
endorsement from medical bodies.  
This is a more than 3-fold increase since 2014 where only 4 of 39 apps (n=4, 10.3%) reported 
clinician input.  
User Perception of Apps 
The Android Apps reviewed had been downloaded between 50 and 500000 times. Android does not 
offer exact download numbers, instead grouping apps into brackets. The most downloaded app fell 
into the 100,000-500,000 bracket. Download data was unavailable for Apple Apps (Table 4).  
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On both Android and Apple, apps were rated from 0 to 5 with 5 being the best score possible. Most 
Android Apps (n=20, 91%) were rated and achieved a mean rating of 3.5 (range 1.6 to 4.6); of the rated 
Apple Apps (n=13, 40%) mean rating was 3.5 (range 1 to 5) (Table 1) 
 
Apps with professional or clinician input appear also to have higher mean user ratings on both Apple 
and Android (Table 3).  
 
Discussion: 
This review shows a 2017 melanoma App market that is characterized by rapid turnover, but also 
ongoing detachment from a firm evidence base backing App efficacy even by the broadest definitions. 
It extends previous reviews by also summarising consumer ratings.   
Rapid Turnover of App Market 
Overall, 56.4% of apps found by Kassianos et al’s in 2014 were no longer available4 and 55.8% of apps 
found in this review are new. The main purpose of the apps on the market has also changed. In 2014, 
the most common functionality was education on melanoma prevention, while in 2017 the majority 
of apps were for monitoring/tracking of skin lesions.  
 
Changing Functional Focus  
The proportion of aps offering algorithmic image analysis approximately halved from 46.2% in 2014 
to 23.3% in 2017. This decline may parallel a growing body of evidence for a lack of efficacy for apps 
providing automated diagnosis or risk-assessment7-9, 14. The FDA ordered the closure of some of these 
type of Apps in 201515 due to insufficient evidence. Alternatively, this decline in numbers may simply 
reflect an increasing market share by successful Apps. In line with this, the most frequently 
downloaded App on the Android store is an App which algorithmically analyses skin lesions (Table 4). 
There is also a new generation of algorithm analysis Apps which track changes between images taken 
by users over time. The app does not aim to diagnose from single images, but rather diagnoses 
changes between images, one of the key signs of malignancy in pigmented lesions2.  
 
Costs  
There is a great potential cost benefit to the consumer if melanoma apps aid in early detection and 
treatment of melanoma. The many different models of payment make direct comparisons of costs 
difficult, but there does not yet exist a proven correlation between the cost of apps and outcomes. 
Particularly in health care systems where care is expensive or difficult to access due to distance or wait 
times, there is a risk that after paying for and receiving reassuring advice from an app a patient may 
neglect to seek appropriate medical care.  
 
Clinician, Scientific and Professional Association with App Development 
Since 2014, the proportion of apps specifically mentioning clinician or scientific input in app 
development has increased nearly 3 fold from 10.3% to 30.2% (Table 4). This is comparable to Apps in 
other health areas. For example Apps for urolithiasis or  colorectal cancer have health care 
professional involvement 32%16 and 36%17 respectively thus it is reassuring that apps for melanoma 
are approaching levels of professional involvement seen in other areas. Unfortunately, independent, 
published peer-review validation of apps remains uncommon. This review found that only 2 of the 43 
apps mentioned peer-reviewed research validating their model of care. This is only a small increase 
from 2014, when only one app had peer-reviewed evidence.  
 
The limited evidence base is complicated by the public availability and rating system in which 
consumer perceptions, not evidence, is often the guide of which App consumers choose to use. On 
AC
CE
PT
ED
 M
AN
US
CR
IPT
both Apple and Android stores, user ratings for Apps which have clinical or scientific input in their 
development had a higher mean rating. However, the two Apps that had peer-reviewed research 
validating their model of care rated only at or below the mean rating for Apple or Android Apps, 
respectively. Previous studies have shown that up to 77% of users of smartphone health App never 
check the credibility of developer or publishers, which may explain the low correlation between  peer-
reviewed evidence and user satisfaction12.  
 
It must be recognised that this study may have underestimated the degree to which  Apps have been 
scientifically studies or undertaken steps towards validation. Some apps may have conduct validation 
internally as part of their development process, but not published about this. As stated earlier, it was 
for this reason a definition of input alone or peer review was used. While peer review is certainly the 
gold standard, involvement or testing by clinicians, scientists or the scientific community associated 
with each app may provide some confidence in its standing. Currently, there does not yet exist a 
standardized measure in the melanoma app development community to recognize the degrees of 
confidence professional  input represent. 
 
Summary 
Clearly, this review provides a broad overview of how the Melanoma App market has evolved since 
2014. Nevertheless, the findings of this study have some key limitations. First, apps may have much 
more evidence backing for their efficacy than is publicly available. Many developers likely conduct 
their own private research, and do not necessarily publish this in academic or industry journals. This 
study could only assess published evidence and therefore may underestimate the degree of scientific 
and clinician involvement in app development. Secondly, user perceptions of apps, while assessed in 
this study, may not necessarily be an accurate reflection of actual consumer satisfaction or efficacy of 
the apps. For example, an app more widely used by consumers may have more reviews and therefore 
have a lower aggregate rating. More research into user perceptions of apps and how the rating system 
influences users’ objective and subjective outcomes needs to be conducted for this data to be most 
meaningful. 
 
Conclusions 
This review demonstrates that since 2014, the nature and types of apps offered to community, patient 
and generalist clinicians for primary and secondary prevention of melanoma has changed significantly. 
Available apps are still largely without evidence-base and many provide a service at very significant 
cost to the users. It is important that developers demonstrate via peer-review the efficacy of their 
apps in achieving its stated goals. Additionally, more work must be done into examining how users 
respond to factors such as app ratings and costs. Skin Cancer Apps may indeed hold potential to 
improve how prevention and early detection of melanoma is delivered . To achieve this promise 
however, , there needs to be a more rigorous scientific testing to ensure consumers are receiving 
appropriate information from their Melanoma Apps. 
 
Summary Table 
What was already known on the topic: 
 There exist many Melanoma Apps to aid users in primary and secondary prevention of 
skin cancer 
 The most common functionality of these apps as of 2014 was in educating users on skin 
cancer and sun protection 
 Many of these apps have a very limited evidence base though are easily available to the 
wider public  
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What this study added to our knowledge 
 The Melanoma App market is a high turnover one – almost half of Apps in 2014 no longer 
existed in 2017 
 The evidence base of many of these Apps is improving however remains limited with the 
vast majority of Apps not peer reviewed or associated with clinician or scientific 
involvement in their development or review  
 The costs of the Apps, especially those providing clinician consultations are significant and 
may be prohibitive for many users 
 The most common function of melanoma Apps in 2017 is in aiding users to monitor and 
track their own moles over time. 
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Table 1: Summary of Findings of 2017 Melanoma App Register  
Aspect 2017 20146 
Number of Apps 43 Apps 39 Apps 
 
Apps offline since 
2014 
17/39 Apps found in 2014 are no longer available (56% 
attrition) 
 
Most common 
functionality 
Monitoring/tracking of skin lesions (n=24, 55.8%) Education about melanoma prevention or skin cancer prevention  
(n=22, 56.4%) 
Costs to Consumers 23 (53.5%) free 
20 (46.5%) requiring payments 
- 9 Apps require “One off” purchases – $0.99 – $6.99 
(mean $3.43) 
- 3 Apps require “subscriptions”. For 12 mths – $13.82 to 
$37.20 (mean $26.81) 
- 7 Apps are “pay per consultation” - $15 to $300.96 
- 1 App is requires purchased dermoscopic attachments for 
full functionality ($99 or $299) 
28 (71.8%) free 
11 (28.2%) required payments 
User Perception1 Android Apple  
Mean rating: 3.5 (20 apps 
had reviews) 
Mean Rating: 3.5 (13 apps 
had reviews) 
Professional, 
Scientific or 
Clinician Input2 
15 (34.9%) Apps  4 (10.3%) Apps  
1All ratings were between 0 to 5, with 5 being best score possible 
2Defined as the App specifically mentioning clinician or scientific input into development or published peer reviewed articles validating efficacy AC
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Table 2: Smartphone Applications for primary or secondary prevention of melanoma for nonspecialist users in the community, patient populations and 
generalist clinicians 
Name of App Owner/Developer Country of Origin Operating System Cost Notes Available 
in 2014 
ApreSkin You- Track your 
Moles, Skin 
Cancers/Melanomas and 
Blemishes 
3D Medical Software 
Pty Ltd 
Australia Apple $1.99 Provides patients with a 3D digital rendition of their body in which 
they can “molemap” the locations of skin spots and monitor them 
for changes over time. It provides reminders to improve 
monitoring. Clinicians can also monitor their patient’s lesions 
through the App and even create reports on lesions.  
 
Be Skin Smart MEDA Pharma South 
Africa 
South Africa Apple Free Calculates a patient's skin cancer risk via a patient answering a 
questionnaire on their skin, eye and hair color. Has a "protection 
timer" which calculates how long a person can stay in the sun 
based on skin type and sunscreen SPF.  
 
Beware of the Sun Portuguese Cancer 
League 
Portugal Apple Free Provides education on UV Risk and Sun Exposure  
 Derma Compare Emerald Medical 
Applications̀ 
Israel Both Free Following a maxim of "Take, Track, Treat", patients take photos of 
skin lesions and monitoring reminders are provided. The App has 
an algorithm which analyses subsequent images for evidence of 
change.  Teledermatology functionality will reportedly be 
integrated into the App soon. 
 
Derma Pic Joshua Meador Unknown Apple $0.99 for App; $2.99 to 
remove ads 
Allows patients to take photos of skin lesions and log the location 
and date of the image. Patients can set reminders for monitoring.  
 
DermatologistOnCall - 
Online Dermatology Care 
DermatologistOnCall ® U.S.A. Apple $59 per consultation Connects patients with local dermatologists. Photos are uploaded 
along with a brief personal and skin lesion history. Diagnosis and 
treatment plans are provided following clinician review.  Has 
subapps which function through the same system and are 
connected with local Dermatology clinics in the United States 
(Advanced Dermatology and Skin Cancer Center - Missouri; 
DermConnect - Florida; Island Dermatology - New York) 
✓  
Dermatology Planet Edizioni Scripta 
Manent snc 
Italy Apple Free Provides patients and clinicians with information on the nearest 
specialist dermatology practice and latest dermatology research 
news 
✓  
First Derm: Online 
Dermatology 
iDOC24 Inc U.S.A. Both $45 per item assessed Patients take photos of their skin lesions and provide a brief 
personal (age, sex) and lesion history. Patient's choose a 
dermatologist associated with the application and this information 
is submitted anonymously for review and response within 24hrs. 
Has reportedly been peer-reviewed for efficacy.  
 
Firstcheck Skin Firstcheck Skin New Zealand Both $15 per image  
analysed; $22.56 for 
FirstCheck Skinscope 
attachment  
Patients take photos of their skin lesions and provide a brief lesion 
history. Patient's choose a dermatologist associated with the 
application and this information is submitted anonymously to a 
local skin specialist (General Practitioner or Dermatologist) for 
review and response within 72hrs. For superior imaging, offers 
users a purchasable FirstCheck SkinScope Attachment. Reportedly 
only for Australia and New Zealand currently.  
 
FotoSkin Wake App Health Spain Both Free Allows patients to log their suspicious skin lesions on a rendition of 
the human body to facilitate monitoring. Also provides reminders 
✓  
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to ensure monitoring is regular. It offers primary prevention 
information on topics including local UVR risk, individual patient 
fototype and skin cancer risk.  
iDOC24 iDOC24 Inc Sweden + USA Both $45USD per item 
assessed 
Patients take photos of their skin lesions and provide a brief 
personal (age, sex) and lesion history. They then choose a 
dermatologist associated with the application and this information 
is submitted anonymously to the clinician for review and response 
within 24hrs. Has reportedly been peer-reviewed for efficacy.  
Same description as First Derm: Online Dermatology and owned by 
same company though the differences between the two services is 
not clear.  
✓  
Know Your Own Skin LEO Pharma A/S U.S.A. Apple Free Allows patients to take photos of skin lesions and log the location 
and date of the image. Also allows setting of reminders for 
monitoring. Provides information on topics such as skin self-
examination and sun exposure/UVR reduction.  
 
LoveMySkin Steven Romej U.S.A. Apple $0.99 Allows patients to take photos of skin lesions and log the location 
and date of the image. Also allows setting of reminders for 
monitoring.  
✓  
Lubax Lubax USA Apple Free Targeted only at Generalist Clinicians. Images are taken of skin 
lesions. Following this, the App uses image recognition technology 
to search databases of images to create a list of differential 
diagnoses of the lesion imaged. Aims to utilize user feedback to 
refine the quality of its image recognition technology.  
 
Melanoma Test- Risk 
Calculator for Skin Cancer 
Pears Health Cyber U.S.A. Apple Free Assesses a patient's melanoma risk based on a questionnaire. Also 
provides information on melanoma prevention.  
 
Melanoma Watch Stroika U.K. Apple $0.99 Patients are given information regarding the differences between 
malignant and benign moles and the ABCDE method. Does not 
analyse lesions but allows users to compare imaged skin lesions 
and stored images of benign and malignant skin lesions side by 
side.  
✓  
Melnaoma iABCD rule Mindexs Brazil Apple Free Teaches users differences between malignant and benign skin 
lesions and the ABCDE method.  
✓  
Miiskin Miiskin Denmark Android Free Allows patients to take photos of skin lesions and log the location 
and date of the image. Also allows setting of reminders for 
monitoring of lesions and provides informational videos regarding 
melanoma and skin cancer.  
 
Mole Checker Stroika U.K. Apple $2.99 Teaches users the ABCDE method and provides examples of lesions 
which are malignant and benign 
✓  
Molexplore Boreal Open Systems Spain Both Free Allows patients to take photos of skin lesions and log the location 
and date of the image and set a date for future reimaging. Patients 
define the "severity' of the lesion in order to guide how soon 
reimaging is required.  Provides a questionnaire for patients to 
define their fototype and risk level along with information on sun 
protection, real time UV index based on patient location and the 
ABCDE method.  
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moleMonitor- Skin Cancer 
Mole Checker 
Pro-Cal Powertrain 
Development 
U.K. Apple $6.99 for App                                             
$31.86 for moleMonitor 
10x Clipon Macro Lens 
Kit 
Only Mole Checker approved by the NHS. Allows patients to take 
photos of skin lesions, log the location and date of the image and 
create reminders for future monitoring. Patient's may purchase a 
moleMonitor Macro Lens (10x zoom) to improve image quality. 
 
MoleScope MetaOptima 
Technology 
Canada Both App – Free; MoleScope 
1 Attachment $99; 
Molescope 2 
Attachment - $299 
Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor. Ideally used with MoleScope Dermoscopy devices in 
order to optimize imaging. Depending on region, images taken can 
be forwarded on to board-certified dermatologists for review. 
 
Mollie’s Fund Mollie Biggane 
Melanoma Foundation 
U.S.A. Both Free Provides information to patients regarding the ABCDE method, skin 
self-examination techniques and sun protection. Can be setup to 
provide reminders to perform monthly skin checks. 
✓  
mSkinDoctor Aleem Technologies Unknown Android Free Classifies uploaded lesion images as malignant or non-malignant 
using a proprietary algorithm. 
 
MySkinMap Xyrupt Technologies, 
LLC 
Unknown Both Free Uses image recognition, machine learning and proprietary 
algorithms to provide a percentage certainty of a lesion being non-
cancerous or cancerous.  
 
Myskinpal MasseranoLabs LLC U.S.A. Both $2.99 Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor. Does not analyze lesions but allows users to view images 
through filters to theoretically improve self-checking of images. 
 
OnlineDermClinic OnlineDermClinic.com U.S.A. Android Fee decided by treating 
physician 
Patients take photos of their skin lesions using a smartphone and 
provide a brief history of the lesion. They then choose a 
dermatologist associated with the App. After paying the clinicians 
fee, this information and image is submitted to the clinician for 
review and response within 24hrs. In 2014 was only on Apple.  
✓  
SelfCheck - Skin Cancer 
Prevention 
Varun Wadhwa Unknown Apple Free Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor. Can connect patients with an App-associated 
dermatologist for review of any lesions they are concerned about.  
 
Skin Analytics Skin Analytics 
Development 
U.K. Android Free one month trial; 
$3.10 per month after 
Allows patients to take photos of skin lesions and log the location 
and date of the image and future reimaging reminders. 
✓  
Skin Cancer Andrew J. Kaufman, MD U.S.A. Apple Free Provides information about the types of skin cancers and 
treatment modalities. Patients can also use the App to identify 
dermatologists nearby and book Appointments 
✓  
Skin Cancer Symptoms Test Examples U.S.A. Android Free Provides information about the symptomology and treatment of 
melanomas, basal cell carcinomas and squamous cell carcinomas  
 
Skin Cancer Symptoms - 
Warning Signs 
Global Appz Ireland Apple $2.99 Provides information about the symptomology and treatment of 
melanomas, basal cell carcinomas and squamous cell carcinomas  
 
Skin MD Now Skin MD Now U.S.A. Android As per local specialist Patients take photos of their skin lesions and provide a brief 
personal (age, sex) and lesion history. Patient's choose a 
dermatologist associated with the App and this information is 
submitted to the clinician for review. Response times are not 
stated.  
 
Skin Mole Analysis Opticom Data Research Canada Android Free Provides access to an online database of moles and their risk 
analysis provided by the company. Images can then be submitted 
✓  
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to an associated dermatologist for analysis. Also advertises to users 
the MoleSense imaging device and software.  
Skin Monitor - Check Your 
Moles 
Skinmonitor.org Unknown Android Free Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
facilitate monitoring. 
 
Skin 
Prevention – 
Photo Body 
Map for 
Melanoma 
and Skin 
Cancer Early 
Detection 
Dimension S.r.l. Italy Apple $6.99 Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
facilitate monitoring.  Reportedly uses a proprietary algorithm to 
analyze and compares subsequent images taken for changes. It 
claims it is promoted by the International Society of Dermatoscopy 
✓  
skinScan TeleSkin ApS Serbia Apple $13.82 for 12 month 
subscription 
Analyzes images taken of a skin lesion with the ABCDE method and 
synthesizes that analysis with the patient's skin cancer risk level 
based on a questionnaire. It uses these two inputs then to classify 
skin lesions as "typical" or "atypical". Also logs the location, date of 
the image and sets a date for future monitoring and reimaging. 
 
SkinTagger Coriumedic Systems LLC U.S.A. Apple Free Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor.  Lesions can be marked on a rendition of the human body 
to help with monitoring.   
✓  
Skinvision Skinvision B.V. Netherlands Both $29.41 for 12 month 
membership 
Analyzes images taken of skin lesions using a proprietary algorithm 
which classifies lesions as "high", "medium" or "low" risk. 
Automatically sets reminders for monitoring of lesions based on 
the risk levels found. Also provides information on UV/Sun 
Exposure protection and melanoma. 
✓  
Smart Skin Check Australia Zoltan Nemeth Australia Apple $300.96 for Total Body 
Mole Documentation 
System Package 
App is part of a Total Body Mole Documentation System which 
involves a qualified mole imaging technologist visiting the patient 
and taking photos of all lesions on a patient's body using the App. 
Images are then forwarded on to two skin specialists for review. 
Repeat images are taken at an unspecified date later and these 
images are compared with the last image set. 
 
Spotmole Cristian Munteanu Spain Android Free Analyzes images of skin lesions using the ABCDE method and 
classifies lesions as "problematic" or "okay".  
✓  
Track-A-Mole Peak Mobile Designs 
LLC 
U.S.A. Android Free Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor.  Patients can compare lesions via watching a slideshow of 
evolution created by the App. Provides information on ABCDE 
method.  
✓  
UM Skin Check Univeristy of Michigan U.S.A. Both Free Allows patients to take photos of skin lesions, log the location and 
date of the image and create future reimaging reminders to 
monitor.  Provides a melanoma risk calculator for 5-year absolute 
melanoma risk, information on ABCDE method, images of common 
skin lesions and UV protection. Validated only for the use in the 
U.S.A. and non-Hispanic whites.  
✓  
ABCDE: A, Asymmetry; B, Border; C, Colour; D, Diameter; E, Evolving; UV: Ultraviolet Radiation; U.S.A.: United States of America; Y:Yes; N: No 
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All “$” symbols refer to US Dollars 
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Table 3: Functional Properties of Smartphone applications for primary or secondary prevention of melanoma for nonspecialist users in the community, patient populations and 
generalist clinicians 
 Information and or Education 
 
Cataloging/Classifying Monitoring or Tracking 
Name of App Melanoma / 
Skin Cancer 
UVR/Sun 
exposure 
advice 
Skin Self 
Examination 
Techniques 
Risk Factor 
Assessment 
Dermoscopic 
Attachment 
Associated 
Image 
Analysis1 
Dermatologist 
Review 
Monitoring/Tracking 
ApreSkin You- Track your Moles, 
Skin Cancers/Melanomas and 
Blemishes 
              ✓  
Be Skin Smart ✓  ✓    ✓          
Beware of the Sun   ✓        ✓    ✓  
Derma Compare           ✓    ✓  
Derma Pic               ✓  
DermatologistOnCall - Online 
Dermatology Care 
            ✓    
Dermatology Planet ✓                
First Derm: Online Dermatology             ✓    
Firstcheck Skin         ✓   ✓   
FotoSkin ✓ ✓ ✓ ✓       ✓ 
iDOC24             ✓   
Know Your Own Skin   ✓ ✓         ✓ 
LoveMySkin               ✓ 
Lubax           ✓     
Melanoma Test- Risk Calculator 
for Skin Cancer 
✓     ✓         
Melanoma Watch ✓ ✓ ✓           
Melnaoma iABCD rule ✓               
Miiskin ✓ ✓ ✓         ✓ 
Mole Checker ✓               
Molexplore ✓ ✓ ✓ ✓       ✓ 
moleMonitor- Skin Cancer Mole 
Checker 
        ✓     ✓ 
MoleScope        ✓   ✓ ✓ 
Mollie’s Fund ✓ ✓ ✓         ✓ 
MSkinDoctor           ✓     
MySkinMap           ✓   ✓ 
Myskinpal           ✓  ✓ 
OnlineDermClinic             ✓   
SelfCheck - Skin Cancer 
Prevention 
            ✓ ✓ 
Skin Analytics               ✓ 
Skin Cancer ✓               
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Skin Cancer Symptoms ✓               
Skin Cancer Symptoms - 
Warning Signs 
✓               
Skin MD Now             ✓   
Skin Mole Analysis             ✓   
Skin Monitor - Check Your 
Moles 
              ✓ 
Skin Prevention – Photo Body 
Map for Melanoma and Skin 
Cancer Early Detection 
          ✓   ✓ 
skinScan ✓     ✓   ✓   ✓ 
SkinTagger               ✓ 
Skinvision ✓ ✓ ✓     ✓  ✓ 
Smart Skin Check Australia             ✓ ✓ 
Spotmole           ✓     
Track-A-Mole ✓   ✓         ✓ 
UM Skin Check ✓ ✓ ✓ ✓       ✓ 
Totals 17 10 9 6 3 10 10 24 
Proportion of Total Apps with 
Functionality Type 
39.5% 23.3% 20.9% 14.0% 7.0% 23.3% 23.3% 55.8% 
Totals in 20142 22 6 15 4 0 18 9 19 
Change Since 20142 -5 -4 +6 -2 +3 -8 +1 +8 
1 Defined as using a proprietary algorithm to analyse images whether this be directly or only to monitor for changes  
2 As per Kassianos et al.6  
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Table 4: Comparison of Community Ratings, Downloads and Date of Last Update against  Professional, Scientific or Clinician Input with Smartphone Applications for primary or secondary 
prevention of melanoma for nonspecialist users in the community, patient populations and generalist clinicians 
 Apple Store Google Play Store  Professional, Scientific or Clinician Input Into Applications 
Name Rating (Out 
of 5) 
Number 
of Raters 
Rating (Out 
of 5) 
Number 
of Raters 
Downloads Last Update Professional Body, 
Scientific or Clinician 
Input  
Peer Review 
Research 
 Organization(s) or individuals involved1 
ApreSkin You- Track 
your Moles, Skin 
Cancers/Melanomas 
and Blemishes 
5 18    Apple: 31-
07-2016 
   
Be Skin Smart IR IR    Apple: 19-
08-2016 
✓  Skin Cancer Foundation of South Africa 
Beware of the Sun IR IR    Apple: 08-
08-2015 
    
Derma Compare 4.5 7 4.1 66  5000-10000 Android:14-
03-2017; 
Apple: 7-01-
2017  
✓  Medical Advisor: Doctor Alan Scope (US Board 
Certified Dermatologist) 
Derma Pic IR IR    Apple: 18-
05-2015 
    
DermatologistOnCall - 
Online Dermatology 
Care 
4 10    Apple: 16-
02-2017 
✓  Creator: Mark P. Seraly MD (Board Certified 
Dermatologist) 
Dermatology Planet IR IR    Apple: 02-
04-2013 
    
First Derm: Online 
Dermatology 
IR IR 3.5 80 10000-50000 Apple: 25-
05-2016 
Android: 
25-05-2016 
✓ ✓ Medical or Scientific Staff on Developing 
Team: Dr John Paoli, Prof. H Peter Soyer, 
Associate Professor Iris Zalaudek, Asfaq A 
Marghoob (MD), Dr Jonathan Bowling, Dr 
Marcus Conant, Dr. Daniel Kraft, Dr. Jordan 
Shlain, Dr Henrik Agrell, Dr Yamini Saripalli 
 
Significant overlap with iDOC24 likely due to 
development by same company. The 
fundamental difference between the two apps 
remains unclear.   
Firstcheck Skin IR IR 4.6 9 1000-5000 Android:04-
05-2017           
Apple 02-
05-2017 
✓  Advisory body: Kevin Sheehy (former GP, 
Health IT), Dr Tom Mulholland (Doctor, 
Telemedicine).  
Support from: Dr Ian Coutts (dermatologist) of 
the New Zealand Dermatology and Skin Cancer 
Centre, Wellington. 
FotoSkin IR IR 3.8 569 50000-100000 Android:02-
03-2016 
✓  Scientific Coordination: Dr. Sergio Vañó. 
Scientific Advisory Body: Dr. Manuel Fernández 
(Dermatologist), Dr. John Paoli (Dermatologist), 
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Apple:13-
10-2015 
Dr Luis Rios (Dermatologist)  
Dr. Pedro Jaén (Head of Department of 
Dermatology of Ramon Ramón y Cajal Hospital 
and Director of the Clínica Grupo de 
Dermatología Pedro Jaén (Madrid, Spain). 
iDOC24 IR IR 3.2 45 5000-10000 Android:05-
03-2016;                   
Apple 31-
10-14 
✓ ✓ Medical or Scientific Staff on: 
 Developing Team: Dr Alexander Börve,  
Dr Dennis Porto, Dr Farhaad Riyaz  
 Advisory Body: Dr Daniel Kraft, Dr 
Jordan Shlain, Dr. Marcus Conant, 
Professor Peter Soyer, Dr Yamini 
Saripalli, Dr Jonathan Bowling, Dr Henrik 
Agrell 
 
Significant overlap with First Derm: Online 
Dermatology likely due to development by 
same company. The fundamental difference 
between the two apps remains unclear.   
Know Your Own Skin 4.5 10    Apple: 17-
12-2012 
    
LoveMySkin 2 28    Apple: 04-
08-2011 
    
Lubax 2.8 11    Apple: 04-
02-2015 
    
Melanoma Test- Risk 
Calculator for Skin 
Cancer 
IR IR    Apple: 07-
04-2017 
    
Melanoma Watch 1.9 13    Apple: 06-
08-2010 
    
Melnaoma iABCD rule IR IR    Apple: 19-
07-2012 
    
Miiskin   4.4 438 50000-100000 Android: 
01-05-2017 
✓  Medical Advisor: Gregor Jemec (MD), Associate 
Professor of Dermatology University of 
Copenhagen 
Mole Checker 1 6    Apple: 16-
07-2010 
   
Molexplore IR IR 4.4 199 10000-50000 Android:24-
04-2017;                    
Apple 26-
04-2017 
✓  Dr Gerard Pitarch (Dermatologist) 
moleMonitor- Skin 
Cancer Mole Checker 
4 16    Apple:11-
10-2016 
✓  Description says it is the only Mole Checker 
approved by the NHS 
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MoleScope IR IR 4.0 22 5000-10000 Android: 
14-03-2017 
✓  Senior Scientist: Prof. Stella Atkins (PhD) 
Scientific Advisors: Prof. Greg Mori (PhD), Tim 
Lee (PhD)                            
Medical Advisors: Dr. David McLean (MD), Dr. 
Harvey Lui (MD), Dr. Jason Rivers (MD), Dr. Ian 
Katz, Giuseppe Argenziano (MD, PHD) 
Mollie’s Fund 5 5 4.8 27 1000-5000 Android:22-
01-2013  
Apple: 19-
02-2011 
    
MSkinDoctor   3.2 15 1000-5000 Android: 
06-02-2016 
    
MySkinMap 4.1 17 IR IR 50-100 Apple: 16-
08-2016                 
Android :07-
09-16 
    
Myskinpal IR IR 3.4 110 10000-50000 Android: 
23-07-2015; 
Apple: 12-
02-2016 
    
OnlineDermClinic   2.9 12 1000-5000 Android: 
30-04-2016 
    
SelfCheck - Skin 
Cancer Prevention 
IR IR    Apple: 03-
09-2016 
    
Skin Analytics   3.2 19 1000-5000 Android: 
22-09-2014 
    
Skin Cancer IR IR    Apple: 03-
05-2014 
✓  Developed by Dr. Andrew Kaufman (MD, FACP) 
Skin Cancer 
Symptoms 
  3.7 23 5000-10000 Android: 
18-01-2015 
    
Skin Cancer 
Symptoms - Warning 
Signs 
IR IR    Apple: 17-
07-2015 
    
Skin MD Now   3.5 34 5000-10000 Android: 
22-12-2013 
    
Skin Mole Analysis   1.6 32 10000-50000 Android: 
23-12-2012 
    
Skin Monitor - Check 
Your Moles 
  3.4 22 1000-5000 Android: 
26-05-2014 
    
Skin Prevention – 
Photo Body Map for 
Melanoma and Skin 
IR IR    Apple: 27-
11-2015 
✓  Promoted by the International Dermoscopy 
Society, Italian Association of Surgery 
Dermatologists (AIDA) 
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Cancer Early 
Detection 
skinScan IR IR    Apple: 29-
05-2017 
✓  Chief Medical Officer: Dr. Bandic (Senior Plastic 
Surgeon and Head of ORS Plastic surgery clinic, 
Belgrade, Serbia) 
SkinTagger IR IR    Apple: 30-
01-2014 
    
Skinvision 2.5 78 2.7 404 100000-500000 Android:20-
04-2017  
Apple: 20-
04-2017 
✓  Scientific Board: Prof. Dedee Murrell (St. 
George Hospital, Sydney), Prof. Thomas Ruzicka 
(Ludwig Maximilian University, Munich), A.Prof. 
Chris Baum (Mayo Clinic, Minnesota) 
Smart Skin Check 
Australia 
IR IR    Apple: 05-
01-2017 
    
Spotmole   2.7 78 10000-50000 Android: 
30-03-2016 
    
Track-A-Mole   1.8 4 500-1000 Android: 
14-08-2011 
    
UM Skin Check 4 37 IR IR 100-500 Apple: 02-
12-2016   
Android: 
02-12-2016 
    
IR - Insufficient Ratings for Ratings to Be Displayed 
Blackened boxes indicate that the App was not available on the relevant operating system 
1All professional titles and descriptions are taken and written as per the websites of the relevant Apps.  
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Appendix 1: Quality and Risk of Bias Checklist for Studies That Review Smartphone Applications 
Criterion Justifications 
1. Has the study clearly mentioned 
the data collection time frame? 
New apps are frequently released and updated. The period in which data collection has taken place is important for further research, which 
may assess the quality of a specific group of health-related apps in relation to time. 
2. Does the study specifically 
mention that the reviewed app 
was downloaded and analysed 
based on its content? 
Reviewing the app description may not be enough to make a full judgement about the app quality. Reporting how apps were initially 
reviewed is necessary to understand the depth of analysis (If it is not mentioned explicitly or only a selected sample is fully downloaded, this 
criterion will not be met) 
3. Does the study clearly describe 
the methods undertaken to 
appraise the app’s quality? 
Describing the assessment methodologies used in app appraisal is essential as it will determine the quality of the review process and dictate 
the usability of the study’s results. (Some studies may describe the results of some quality indicators, but if no quality appraisal criteria is 
explicitly described, this criterion will not be met).  
4. Does the study clearly describe 
the methodology taken to search 
for appropriate apps, including key 
words and search restrictions? 
This will help further research as it will highlight differing means of effectively searching for health-related apps. In addition, it will provide 
evidence as to how thorough the study search process was. The absence of this criterion will prevent future replication of the research.  
5. Does the study clearly mention 
the inclusion and exclusion criteria 
for app selection? 
Providing an explanation for why some apps were included and others excluded increases the likelihood of reproducible results and further 
specifies the types of apps included.  
6. Does the study identify the 
country in which the search was 
conducted? 
Some app stores such as the Apple App Store and Google Play allow developers to restrict the purchasing of apps to specific countries. 
Therefore the search results may vary as they are country dependent.  
7. Does the study clearly identify the 
targeted group of users the app is 
intended for (consumers or 
healthcare professionals)? 
Identifying the intended audience for the apps is important to allow for comparison of app quality within targeted groups.  
8. Does the study provide a list of 
apps included in the review? 
Providing the final apps included in the study will help future researchers to monitor the progress and quality of apps that may have been 
updated over time.  
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Appendix 2 – Flowchart and Search Terms Used to Collate Melanoma App Register  
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Apple and Android Stores 
Searched using Key Terms 
 “Skin Cancer” 
 “Mole” 
 “Melanoma” 
 Skin  
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Apple and Android Stores 
Searched using app names 
previously featured in 
Kassianos et al. 2014 review 6 
(see full list below) 
 
Duplicates Removed 
Apps Excluded if: 
 Targeted at specialist clinicians (dermatologists, plastic surgeons) 
 Not in English 
 Cosmetically focused 
 Entertainment Tools 
 Booking tools for skin cancer clinics 
43 Eligible Apps Found  
43 Apps downloaded and data 
extracted for quantitative and 
qualitative analysis I
n
cl
u
d
ed
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Full List of Specific Search Terms Used As Per Kassianos Et Al.  
 ABCDEs of melanoma 
 Dermatology Planet 
 Dermlink.md 
 Doctor Mole – Skin Cancer App 
 Doctor Mole 
 Embarrassing Bodies – My MoleChecker 
 Embarrassing Bodies – My SelfChecker 
 Embarassing Bodies 
 FotoSkin 
 IDoc24 
 iDoc24 – Ask the dermatologist today! 
 iSkin 
 LoveMySkin – Mole map for skin cancer prevention 
 LoveMySkin 
 Melanoma iABCD rule 
 Melanoma Visual Risk Calculator 
 Melanoma Watch 
 Mole Check App 
 Mole Checker 
 Mole Checker 
 Mole Detective 
 Mole Monitor 
 MoleQuest 
 MoleTrac 
 Mollie's Fund 
 nēvus  
 OnlineDerm Clinic 
 Skin Analytics 
 Skin Cancer 
 Skin Cancer Information 
 Skin Doctor 
 Skin Mole Analysis 
 Skin of Mine 
 Skin Prevention – Photo Body Map for Melanoma and Skin Cancer Early Detection 
 Skin Scanner 
 SkinTagger 
 SkinVision 
 SkinXM 
 SpotCheck 2 
 SpotMole 
 Track‐A‐Mole 
 UMSkinCheck 
 YourSkinDiary AC
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